– Commitment Extends Support to Rising Need in California, North Carolina, New Jersey, Maryland, and Washington, D.C. – The funding focuses on reducing barriers to fresh food in vulnerable communities ...

Gilead Sciences (GILD) stock has drawn the attention of investors with its recent performance over the past month, gaining about 4%. With steady annual revenue and net income growth, there is renewed ...

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Gilead Sciences has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. After comparing two phase 1 integrase strand transfer inhibitors, the Bay Area pharma ...

On Oct. 6, Gilead Sciences GILD announced a settlement with three generic manufacturers, securing an agreement for them not to launch a generic version of the firm’s HIV drug Biktarvy in the United ...

Thanks to new settlement agreements with three generic drug makers, Gilead Sciences has extended the expected life span of its flagship HIV treatment Biktarvy by as many years. Gilead has struck ...

While Gilead Sciences previously ponied up hundreds of millions of dollars to resolve kickback allegations related to its HIV business, the company this week triumphed over a whistleblower lawsuit ...

Gilead Sciences broke ground on its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company’s Foster City headquarters in California. This milestone ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday. The HIV drug maker reported adjusted earnings of $2.01 per ...

Gilead raises full-year outlook, cites strong HIV drug sales Quarterly earnings flat, revenue up 2% to $7.1 billion HIV sales rise 7% to $5.1 billion Aug 7 (Reuters) - Gilead Sciences (GILD.O), opens ...

Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...

Taking PrEP (pre-exposure prophylaxis) before exposure can help prevent HIV. Low- and middle-income countries will be able to purchase an effective preventative at a reduced price. The arrangements ...